The Ophthalmic Pharmaceutical Market Outlook To 2014: Competitive landscape, pipeline analysis, growth opportunities and market forecasts

Table of Contents

Executive summary

• Overview and epidemiology
• Global market analysis
• Pipeline analysis
• Competitive landscape

Chapter 1 - Scope and methodology

• Scope
• Methodology

Chapter 2 - Overview and epidemiology

• Summary

• Introduction
• Blindness facts

• Cataracts
• Background
• Treatment and management
• Forecast epidemiology

• Glaucoma
• Background
• Treatment and management
• Forecast epidemiology

• Retinal disorders
• Age-related macular degeneration
  • Treatment and management
  • Forecast epidemiology
• Diabetic retinopathy and diabetic macular edema
  • Treatment and management
  • Epidemiology

• Dry eye syndrome or (keratoconjunctivitis sicca)
• Background
• Treatment and management
• Forecast epidemiology

Chapter 3 - Global market analysis

• Summary
• Introduction
• Historical growth trends
• Regional dynamics
• Leading ophthalmic brands
• Market analysis by drug class
• Forecast market performance drug class wise

• Key issues
• Patent cliff looms in the ophthalmic market

• Key events
• Novartis' acquisition of Alcon

• Anti-glaucoma preparations
• Leading brands
• Brand analysis
• Leading players

• Ocular anti-neovascularization preparations
• Leading brands
• Brand analysis
• Leading players

• Artificial tears
• Leading brands
• Brand analysis
• Leading players

• Ocular anti-allergics, decongestants and antiseptics
• Drug class analysis
• Leading brands
• Brand analysis
• Leading players

• Ophthalmic anti-infectives and anti-inflammatory preparations
• Drug class analysis
• Leading anti-infective brands
• Key brand analysis
• Leading anti-inflammatory brands
• Key brand analysis
• Leading anti-infectives/anti-inflammatory combination brands
• Key brand analysis
• Leading players

• Miscellaneous ophthalmic preparations
• Leading brands

Chapter 4 - Pipeline analysis

• Summary

• Introduction
• Key trends, issues and events
  • Protracted regulatory pathway presents entry barriers to the high-growth DES segment
  • Drug implant techniques: economic alternative to laser therapy in DME
  • AMD treatment that uses VEGF-targeted siRNA strategies is in troubled waters
• Recently launched products
  • Besivance
  • Ozurdex
• Products in Phase III
  • Bepreve
  • Prolacria
  • VEGF Trap-Eye
  • Luveniq
• Products in Phase II
  • iDestrin
  • Ecabet
  • Androgen Tears
• Pipeline forecasts

Chapter 5 - Competitive landscape

• Summary
• Introduction
• Market concentration/fragmentation analysis
• Sales performance of leading players
• Positioning of major players in 2008 by segment

• Forecast sales performance of leading players
• Alcon
  • Overview
  • Dependency on ophthalmic business
  • Drug class focus
  • Marketed portfolio
  • Pipeline portfolio
  • Competitive analysis
• Allergan
  • Overview
  • Dependency on ophthalmic business
  • Drug class focus
  • Marketed portfolio
  • Pipeline portfolio
  • Competitive analysis
• Pfizer
  • Overview
  • Dependency on ophthalmic business
  • Drug class focus
  • Marketed portfolio
  • Pipeline portfolio
  • Competitive analysis
• Novartis
  • Overview
  • Dependency on ophthalmic business
  • Drug class focus
  • Marketed portfolio
  • Pipeline portfolio
  • Competitive analysis
• Merck & Co.
  • Overview
  • Dependency on ophthalmic business
  • Drug class focus
  • Marketed portfolio
  • Competitive analysis
• Santen Seiyaku
  • Overview
  • Dependency on ophthalmic business
  • Drug class focus
  • Marketed portfolio
  • Pipeline portfolio
  • Competitive analysis
• Bausch & Lomb
  • Overview
  • Dependency on ophthalmic business
  • Drug class focus
  • Marketed portfolio
  • Pipeline portfolio
  • Competitive analysis

Chapter 6 - Appendix

• Definitions
• Phacoemulsification (Phaco)
• Extracapsular cataract extraction (ECCE)
• Intracapsular cataract extraction (ICCE)
• 20/40 vision

• Glossary

• Index

List of Figures

• Figure 2.1: Leading causes of blindness worldwide (%)
• Figure 2.2: Stages of progression of diabetic retinopathy
• Figure 3.3: Historical growth trend of the ophthalmic market, 2004 - 08
• Figure 3.4: Forecast sales trend in the global ophthalmic market, 2008 - 14
• Figure 3.5: Drivers and resistors of the global ophthalmic market through to 2014
• Figure 3.6: Chronology of significant events in the ophthalmic market through to 2014
• Figure 3.7: Sales analysis of Novartis and Alcon' s merged ophthalmic business through to 2014
• Figure 3.8: Comparison of sales trends of anti-neovascularization preparations , 2004 - 08
• Figure 4.9: Competitive analysis of diabetic macular edema treatments
• Figure 5.10: Competitive position of companies across market segments, 2008
• Figure 5.11: Sales performance trend of Alcon' s pharmaceutical business, 2007 - 08
• Figure 5.12: Sales performance trend of Allergan' s pharmaceutical business, 2007 - 08
• Figure 5.13: Sales performance trend of Pfizer' s pharmaceutical business, 2007 - 08
• Figure 5.14: Sales performance trend of Novartis' pharmaceutical business, 2007 - 08
• Figure 5.15: Sales performance trend of Merck' s pharmaceutical business, 2007 - 08
• Figure 5.16: Sales performance trend of Santen Seiyaku' s pharmaceutical business, 2007 - 08
• Figure 5.17: Sales performance trend of Bausch & Lomb' s pharmaceutical business, 2007 - 08

List of Tables

• Table 2.1: Cataract surgery and commercial opportunity
• Table 2.2: Forecast prevalence of cataracts across the 7MM, 2008 - 14
• Table 2.3: Target IOP and degree of glaucoma
• Table 2.4: Glaucoma management strategies
• Table 2.5: Forecast prevalence of glaucoma across the 7MM, 2008 - 14
• Table 2.6: Forecast prevalence of dry AMD across the 7MM, 2008 - 14
• Table 2.7: Forecast prevalence of wet AMD across the 7MM, 2008 - 14
• Table 2.8: Global prevalence of diabetic retinopathy and diabetic macular edema, 2008
• Table 2.9: Forecast prevalence of dry eye syndrome across major markets, 2008 - 14
• Table 3.10: Regional dynamics in the ophthalmic market, 2007 - 08
• Table 3.11: Sales performance of leading ophthalmic brands, 2007 - 08
• Table 3.12: Sales performance of various ophthalmic drug classes, 2007 - 08
• Table 3.13: Leading brands across drug classes, 2007 - 08
• Table 3.14: Forecast sales performance of various ophthalmic drug classes, 2008 - 14
• Table 3.15: Sales performance of leading anti-glaucoma preparations, 2007 - 08
• Table 3.16: Leading players in the anti-glaucoma preparations segment, 2008
• Table 3.17: Sales performance of leading anti-neovascularization preparations, 2007 - 08
• Table 3.18: Leading players in the ocular anti-neovascularization segment, 2008
• Table 3.19: Sales performance of leading artificial tears, 2007 - 08
• Table 3.20: Leading players in the artificial tears segment, 2008
• Table 3.21: Sales performance of drug classes in the ocular anti-allergics, decongestants and antiseptics segment, 2007 - 08
• Table 3.22: Sales performance of leading ocular anti-allergics, decongestants and antiseptics, 2007 - 08
• Table 3.23: Leading players in the ocular anti-allergics, decongestants and antiseptics segment, 2008
• Table 3.24: Sales performance of drug classes in the ocular anti-inflammatory and anti-infectives market segment, 2007 - 08
• Table 3.25: Sales performance of leading ophthalmic anti-infectives, 2007 - 08
• Table 3.26: Sales performance of leading ophthalmic anti-inflammatory products, 2007 - 08
• Table 3.27: Sales performance of leading anti-infectives/anti-inflammatory combination brands, 2007 - 08
• Table 3.28: Leading players in the ophthalmic anti-infectives/anti-inflammatory segment, 2008
• Table 3.29: Sales performance of miscellaneous ophthalmic preparations, 2007 - 08
• Table 4.30: Milestones of DES
• Table 4.31: Mid- to late-stage siRNA trials
• Table 4.32: Overview of Besivance
• Table 4.33: Overview of Ozurdex
• Table 4.34: Overview of Bepreve
• Table 4.35: Overview of Prolacria
• Table 4.36: Overview of VEGF Trap-Eye
• Table 4.37: Overview of Luveniq
• Table 4.38: Overview of iDestrin
• Table 4.39: Overview of ecabet
• Table 4.40: Overview of Androgen Tears
• Table 4.41: Pipeline forecasts, 2008 - 14
• Table 5.42: Sales performance of leading players in the ophthalmic market, 2007 - 08
• Table 5.43: Forecast sales performance of leading players in the ophthalmic market, 2008 - 14
• Table 5.44: Alcon' s ophthalmic sales performance by drug class, 2007 - 08
• Table 5.45: Sales performance of Alcon' s leading ophthalmic brands, 2007 - 08
• Table 5.46: Alcon' s ophthalmic pipeline portfolio, July 2009
• Table 5.47: Allergan' s ophthalmic sales performance by drug class, 2008
• Table 5.48: Sales performance of Allergan' s leading ophthalmic brands, 2007 - 08
• Table 5.49: Allergan' s ophthalmologic pipeline portfolio, July 2009
• Table 5.50: Pfizer' s ophthalmic sales performance by drug class, 2008
• Table 5.51: Sales performance of Pfizer' s leading ophthalmic brands, 2007 - 08
• Table 5.52: Pfizer' s ophthalmologic pipeline portfolio, July 2009
• Table 5.53: Novartis' ophthalmic sales performance by drug class, 2007 - 08
• Table 5.54: Sales performance of Novartis' leading ophthalmic brands, 2007 - 08
• Table 5.55: Novartis' ophthalmologic pipeline portfolio, July 2009
• Table 5.56: Merck' s ophthalmic sales performance by drug class, 2008
• Table 5.57: Sales performance of Merck' s leading ophthalmic brands, 2007 - 08
• Table 5.58: Santen Seiyaku' s ophthalmic sales performance by drug class, 2008
• Table 5.59: Sales performance of Santen Seiyaku' s leading ophthalmic brands, 2007 - 08
• Table 5.60: Santen Seiyaku' s ophthalmologic pipeline portfolio, July 2009
• Table 5.61: Bausch & Lomb' s ophthalmic sales performance by drug class, 2008
• Table 5.62: Sales performance of Bausch & Lomb' s leading ophthalmic brands, 2007 - 08
• Table 5.63: Bausch & Lomb' s ophthalmologic pipeline portfolio, July 2009